Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization

Human Antibodies

Volumn 17, Issue 3-4, 2008, Pages 79-84

  Aghaie, A ^a   Pourfatollah, A A ^b   Bathaie, S Z ^b   Moazzeni, S M ^b   Pour, H Khorsand Mohammad ^a   Sharifi, Z ^a  

^a IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Intravenous immunoglobulin; Pasteurization; Solvent detergent; Validation; Virus inactivation

Indexed keywords

DETERGENT; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G; ORGANIC SOLVENT; POLYSORBATE 80; TRIBUTYL PHOSPHATE;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; BOVINE DIARRHEA VIRUS; CYTOPATHOGENIC EFFECT; DRUG FORMULATION; DRUG SAFETY; HELA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PASTEURIZATION; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REOVIRUS; VERO CELL; VESICULAR STOMATITIS VIRUS; VIRUS INACTIVATION; VIRUS NEUTRALIZATION;

EID: 56649099171     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-2008-173-405     Document Type: Article

References (19)

1. World Health Organization, 2004. WHO Technical Report, Series No.924.
2. C. Kempf, M. Stucki and N. Boschetti, Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins, Biologicals 35 (2007), 35-42.
3. K. Chidwick, P. Matejtschuk, E. Gascoigne, N. Briggs, J.E. More and C.H. Dash, Clinical experience with a new solvent detergent treated intravenous immunoglobulin free of hypotensive effects, Vox Sanguinis 77 (1999), 204-209.
4. S. Chandra, A. Groener and F. Feldman, Effectiveness of alternative treatments for reducing potential viral contaminants from plasma - derived products, Thrombosis Research 105 (2002), 391-400.
5. O.M. Espindola, M.S.P. Belluci, B.C.E.P.D. Oliveira, M.I.M. Liberto and M.C. Cabral, Sinbis virus as a tool for quality control of viral inactivation of heated and chemically treated plasma-derived products, Journal of virological methods 134 (2006), 171-175.
6. M. Farshid, Viral safety evaluation of plasma - derived therapeutic products, Dev Biol 118 (2004), 11-15.
7. CPMP/BWP/268/95: Virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses, 1996.
8. T. Burnouf and M. Radosevich, Reducing the risk of infection from plasma products: specific preventative strategies, Blood Review 14 (2000), 94-110.
9. E.J. Cohn, L.E. Strong, W.L. Hughes, D.J. Mulford, J.N. Ashwort, M. Melin and H.L. Taylor, Preparation and properties of serum and plasma proteins, J Am Chem Soc 68 (1946), 459-475.
10. A. Aghaie, A.A. Pourfathollah, S.Z. Bathaie, S.M. Moazzeni, H. Khorsand Mohamad Pour, H. Rezvan, S. Banazadeh, B. Adibi, M.K. Mosavi and M.A. Jalili, Preparation of the intermediate product suitable for production of IVIg, Blood (Khoon) 3 (2006), 101-110.
11. B.W.J. Mahy and H.O. Kangro, Virology methods manual. Quantitation of virus. Academic press, ISBN 0-12 465-330-8, 1996.
12. A. Aghaie, A.A. Pourfathollah, S.Z. Bathaie, S.M. Moazzeni, H. Khorsand Mohamad Pour and S. Banazadeh, Structural Study on Immunoglobulin G Solution after Pasteurization with and without Stabilizer, Transfusion Medicine 18 (2008), 62-70.
13. B. Eriksson, L. westman and M. Jernberg, Virus validation of plasma derived products produced by Pharmacia, with particular reference to immunoglobulin, Blood Coagul Fibrinolysis 5(suppl 3) (1994), S37-44.
14. M. Stadler, G. Gruber, C. Kannicht, L. Biesert, K.U. Radomski, H. Suhartono, K. Pock, A. Neisser-Svae, J. Weinberger, J. Romisch and T.E. Svae, Characterisation of a novel high- purity, double virus inactivated von willebrand factor and factor VIII concentrate (Wilate®), Biologicals 34 (2006), 281-288.
15. T. Burnouf, Integration of chromatography with traditional plasma protein fractionation methods, Bioseparation 1 (1991), 383-396.
16. B. Just and H. Lefevre, Detection of parvovirus B19 DNA in solvent-detergent plasma, Vox Sanguinis 83 (2002), 167-168.
17. C.E. Chang, H.G. ED, Y.S. Lee, S.K. Chung, J.S. Shin, Y.K. Lah, C.W. Park, J.T. Jung, J.W. Huh and S.M. Lee, Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment, Prep Biochem Biotechnol 31(1) (2001), 81-82.
18. F.G. Terpstra, J. Parkkinen, H. Tölö, A.H.L. Koenderman, H.G.J. ter Hart, L. von Bonsdorff, E. Törmä and F.A.C. van Engelenburg, Viral safety of Nanogam®, a new 15 nm-filtered liquid immunoglobulin product, Vox Sanguinis 90 (2006), 21-32.
19. J. Blumel, I. Schmidt, H.Willkommen and J. Lower, Inactivation of parvovirus B19 during pasteurization of human serum albumin, Transfusion 42 (2002), 1011-1018.